Black Diamond Therapeutics, Inc. Common Stock

BDTXNASDAQ • USD
ThemeHealthcare - Oncology›Targeted Therapy & Precision Oncology
1.47 USD
↘ 0.05 (3.29%)AT CLOSE (03:59 PM EST)
1.53
↗ 0.06 (4.15%)
POST MARKET (AS OF 04:14 PM EST)
Post Market
AS OF 04:14 PM EST
1.53
↗ 0.06 (4.15%)
🔴Market: CLOSED

Black Diamond Therapeutics, Inc. Common Stock (BDTX) trades at $1.47 per share. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On the valuation side, BDTX appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Nov 13, 2026.

Open?$1.55
High?$1.57
Low?$1.45
Prev. Close?$1.52
Volume?902.9K
Avg. Volume?854.0K
VWAP?$1.52
Rel. Volume?1.06x
Bid / Ask
Bid?$1.45 × 3.8K
Ask?$1.61 × 300
Spread?$0.16
Midpoint?$1.53
Valuation & Ratios
Market Cap?84.5M
Shares Out?57.5M
Float?42.5M
Float %?74.1%
P/E Ratio?N/A
P/B Ratio?0.96
EPS?-$0.77
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Themes
Healthcare - Oncology›Targeted Therapy & Precision OncologyBiotech - Drug Development›Clinical-Stage Platforms
Employees
21
Market Cap
87.4M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.blackdiamondtherapeutics.com
Listed
2020-01-30
Address
245 FIRST STREET, 18TH FLOOR
CAMBRIDGE, MA 02142
Phone: 617-417-5868
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
50
Short Sent.?
40
Piotroski F-Score?0/9Weak
Altman Z-Score?-4.71Distress
Confidence?54%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?12.00%High
Short Interest?5.1M
Days to Cover?4.9
Free Float42.5M
Avg Daily Volume1.0M
Settlement Date2026-10-30
Financial Health
Current Ratio?6.92Strong
Quick Ratio?6.92Strong
Cash Ratio?0.98Adequate
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.96CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.5CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-50.0%WEAK▾
ROA?
S&P
3
-38.1%WEAK▾
Cash Flow & Enterprise
FCF?$-33325000
Enterprise Value?$69.4M
Fundamentals ratios updated end of day
MarketsMoversWatchlist